ESTRASIGN 2 TAB is an advanced formulation designed for oral administration, containing Estradiol Valerate 2 mg, a synthetic prodrug of estradiol, the primary endogenous estrogen hormone in women. Estradiol Valerate is rapidly converted in the body to 17β-estradiol, which then binds to estrogen receptors in various tissues to regulate vital physiological functions. This formulation is most commonly used in postmenopausal women for the management of vasomotor symptoms such as hot flashes, night sweats, mood swings, and vaginal dryness caused by decreased estrogen levels. Additionally, it serves in the treatment of ovarian failure, hypogonadism, primary amenorrhea, and as part of transgender hormone therapy (MTF).

BluepillExpress produces ESTRASIGN 2 TAB with high-quality API under internationally compliant manufacturing processes that meet the quality expectations of regulated and semi-regulated markets. The product is available with full technical documentation including COA, stability data, and CTD/ACTD dossiers to support global regulatory submissions.

The hormone estradiol in ESTRASIGN 2 TAB mimics natural estrogen activity, acting on reproductive tissues, bones, cardiovascular system, and skin. It promotes the development and maintenance of secondary sexual characteristics and has a protective effect on bone density and lipid metabolism in postmenopausal women. ESTRASIGN 2 TAB is indicated as a monotherapy in women who have had a hysterectomy or in combination with progestin therapy to prevent endometrial hyperplasia in women with an intact uterus.

Pharmacokinetically, Estradiol Valerate is absorbed rapidly after oral administration, undergoing hydrolysis in the gastrointestinal tract and liver to yield estradiol and valeric acid. It exhibits high first-pass metabolism, with therapeutic levels achieved typically within hours. The terminal half-life of estradiol following administration is approximately 13 to 20 hours, depending on individual metabolism and liver function. Estradiol is primarily excreted in urine as glucuronide and sulfate conjugates.

ESTRASIGN 2 TAB is typically prescribed as a once-daily oral tablet, with dosage regimens varying based on the specific indication, patient age, and therapeutic goals. In menopausal hormone therapy, treatment usually begins with a low dose, which may be titrated based on symptom control and patient tolerance. For younger women requiring estrogen replacement due to ovarian insufficiency or hypogonadism, higher doses may be employed under medical supervision.

The use of ESTRASIGN 2 TAB is contraindicated in patients with a known history of estrogen-dependent tumors such as breast cancer or endometrial carcinoma, active or recent thromboembolic disorders, liver dysfunction, or undiagnosed abnormal vaginal bleeding. It should also be used with caution in patients with hypertension, diabetes, gallbladder disease, and in smokers over 35 years of age due to increased cardiovascular risk.